|   | |
| Clinical data | |
|---|---|
| Other names | CGS-25248; ZY-15119 | 
| ATC code | 
  | 
| Legal status | |
| Legal status | 
  | 
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H18ClN3O3 | 
| Molar mass | 335.79 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
| (verify) | |
Cebaracetam (INN ; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed. [1] [2] [3]
It is a chlorinated acetyl piperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam). [4] It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety. [4] The mechanism of action of cebaracetam is undefined or unknown. [1]
The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995. [1] It reached phase 2 clinical trials prior to its discontinuation. [1]